Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population, together with additional emerging agents with novel MOAs and a general increase in the use of biologics to maintain disease control, will help drive market growth. In contrast to these factors, the expected generic entry of leading branded conventional agents (e.g., Shire’s Lialda), continuing generic erosion of other conventional agents, and the additional entries and expanded use of less-expensive biosimilar TNF-alpha inhibitors (e.g., Pfizer’s Inflectra, Amgen’s Amjevita) will constrain the UC market. Indeed, given the increasing competition in the UC market—for both branded and generic/biosimilar agents—emerging therapies looking to penetrate this market will need to be clearly differentiated from competitors.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Already a Client? Log in to access this report.
Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science industries. Her other experience includes assessing the scientific and commercial viability of technologies developed in academic labs while working as a fellow at Columbia Technology ;Qinghui Yu holds a from Columbia ;
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.
Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease. He holds a degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.